Mesoblast

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

Company

Indicator

Code Company Date Close Change Indicator Value Signal

Trading Performance

Average True Range

Score

-0.95

Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 7 63.3 0.57% 1.33% 11.1% -17.2% -7.4%
SHORT 7 43.7 0.29% 0.40% 1.9% -9.1% -41.7%

Summary

Technical Analysis

Mesoblast has a TR of 0.04, and an ATR(14) of 0.067.



Average true range (ATR) is a technical analysis volatility indicator originally developed by J. Welles Wilder Jr. for commodities. The indicator does not provide an indication of price trend simply the degree of price volatility.

Calculation: Average True Range (ATR):
1) Current ATR = [(Prior ATR x 13) + Current TR] / 14;
2) Where TR = max[(high-low) abs(high-close previous) abs (low-close previous)]


PROFILE: Mesoblast (MSB.AX)


Stock Exchange: ASX
Company: Mesoblast
Ticker Codes: | MSB.AX | ASX:MSB |

About Mesoblast (ASX:MSB):

Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions. The company's products under the Phase III clinical trials include MPC-150-IM for chronic and end-stage heart failure; MPC-06-ID for chronic low back pain; and MSC-100-IV for acute graft versus host disease in children. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, and diabetic kidney diseases and type 2 diabetes. The company has a collaboration agreement with JCR Pharmaceuticals Co., Ltd. It has operations in the United States, Australia, Singapore, and Switzerland. Mesoblast Limited was founded in 2004 and is headquartered in Melbourne, Australia.

Top 10:

Average True Range

Download
Company Close Change(%) Volume Value Signal
APX Appen 22.66 5.9 1,026,466 0.93 NEUTRAL
NMT Neometals 0.2 5.3 241,577 0.01 NEUTRAL
DTL Data#3 3.43 5.2 1,162,137 0.19 NEUTRAL
BSE BSE 0.22 4.9 77,053 0.01 NEUTRAL
SMN Structural Monitoring Systems 0.98 4.8 47,285 0.05 NEUTRAL
SGF SG Fleet 2.68 4.7 164,520 0.08 NEUTRAL
BEE Broo 0.02 4.5 172,843 0.01 NEUTRAL
SHM Shriro 0.72 4.3 7,177 0.02 NEUTRAL
PSQ Pacific Smiles 1.77 4.1 3,500 0.04 NEUTRAL
KAR Karoon Gas Australia 1.1 3.8 5,014,070 0.05 NEUTRAL